1. Home
  2. NVTS vs IMNM Comparison

NVTS vs IMNM Comparison

Compare NVTS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navitas Semiconductor Corporation

NVTS

Navitas Semiconductor Corporation

HOLD

Current Price

$7.88

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$17.93

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVTS
IMNM
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
NVTS
IMNM
Price
$7.88
$17.93
Analyst Decision
Hold
Strong Buy
Analyst Count
7
17
Target Price
$14.39
★ $35.33
AVG Volume (30 Days)
★ 12.4M
1.5M
Earning Date
11-03-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 51.40
EPS
N/A
★ N/A
Revenue
★ $45,916,000.00
$6,941,000.00
Revenue This Year
$4.02
N/A
Revenue Next Year
$52.24
$18,803.97
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.85
$14.64
52 Week High
$34.17
$30.06

Technical Indicators

Market Signals
Indicator
NVTS
IMNM
Relative Strength Index (RSI) 47.26 49.71
Support Level $7.65 $19.47
Resistance Level $9.57 $23.48
Average True Range (ATR) 0.60 1.18
MACD 0.08 0.47
Stochastic Oscillator 86.07 48.90

Price Performance

Historical Comparison
NVTS
IMNM

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: